GENSCRIPT BIO (01548): Subsidiary Receives New Payment Under License Agreement with LM Pharma

Stock News

Oct 14

GENSCRIPT BIO (01548) announced that its subsidiary has received a new payment of approximately RMB 480 million (equivalent to about $67.5 million, net of withholding taxes) under the restated and amended license agreement with LM Pharma.

This payment represents the second sublicensing revenue related to the licensed anti-PD-1 single domain antibody under the restated and amended license agreement. The anti-PD-1 single domain antibody is being utilized in LM Pharma's development of the investigational PD-1/VEGF bispecific antibody LM-299, which has received approval for clinical trials as a new drug.

As of October 14, 2025, the subsidiary has cumulatively received approximately RMB 2 billion (equivalent to about $284 million, net of withholding taxes) under the restated and amended license agreement.

The receipt of these funds will further strengthen the subsidiary's cash reserves and will be used to support new molecule discovery and development initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1157989732"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157989732\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157989732?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157989732","market":"sh","top_or_hot":-1,"title":"GENSCRIPT BIO (01548): Subsidiary Receives New Payment Under License Agreement with LM Pharma","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) announced that its subsidiary has received a new payment of approximately RMB 480 million (equivalent to about $67.5 million, net of withholding taxes) under the restated and amended license agreement with LM Pharma.</p>\n<p>This payment represents the second sublicensing revenue related to the licensed anti-PD-1 single domain antibody under the restated and amended license agreement. The anti-PD-1 single domain antibody is being utilized in LM Pharma's development of the investigational PD-1/VEGF bispecific antibody LM-299, which has received approval for clinical trials as a new drug.</p>\n<p>As of October 14, 2025, the subsidiary has cumulatively received approximately RMB 2 billion (equivalent to about $284 million, net of withholding taxes) under the restated and amended license agreement.</p>\n<p>The receipt of these funds will further strengthen the subsidiary's cash reserves and will be used to support new molecule discovery and development initiatives.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO (01548): Subsidiary Receives New Payment Under License Agreement with LM Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO (01548): Subsidiary Receives New Payment Under License Agreement with LM Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-14 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) announced that its subsidiary has received a new payment of approximately RMB 480 million (equivalent to about $67.5 million, net of withholding taxes) under the restated and amended license agreement with LM Pharma.</p>\n<p>This payment represents the second sublicensing revenue related to the licensed anti-PD-1 single domain antibody under the restated and amended license agreement. The anti-PD-1 single domain antibody is being utilized in LM Pharma's development of the investigational PD-1/VEGF bispecific antibody LM-299, which has received approval for clinical trials as a new drug.</p>\n<p>As of October 14, 2025, the subsidiary has cumulatively received approximately RMB 2 billion (equivalent to about $284 million, net of withholding taxes) under the restated and amended license agreement.</p>\n<p>The receipt of these funds will further strengthen the subsidiary's cash reserves and will be used to support new molecule discovery and development initiatives.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"","article_id":"1157989732","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157989732","pubTimestamp":1760433866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) announced that its subsidiary has received a new payment of approximately RMB 480 million (equivalent to about $67.5 million, net of withholding taxes) under the restated and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1576":"医药外包概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1515":"抗疫概念","BK1161":"生物科技","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","09939":"开拓药业-B","01548":"金斯瑞生物科技","BK1574":"生物医药B类股","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"金斯瑞生物(01548)：子公司根据与LM Pharma的许可协议收到新付款","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"01548":1,"09939":1},"content_text":"GENSCRIPT BIO (01548) announced that its subsidiary has received a new payment of approximately RMB 480 million (equivalent to about $67.5 million, net of withholding taxes) under the restated and amended license agreement with LM Pharma.\nThis payment represents the second sublicensing revenue related to the licensed anti-PD-1 single domain antibody under the restated and amended license agreement. The anti-PD-1 single domain antibody is being utilized in LM Pharma's development of the investigational PD-1/VEGF bispecific antibody LM-299, which has received approval for clinical trials as a new drug.\nAs of October 14, 2025, the subsidiary has cumulatively received approximately RMB 2 billion (equivalent to about $284 million, net of withholding taxes) under the restated and amended license agreement.\nThe receipt of these funds will further strengthen the subsidiary's cash reserves and will be used to support new molecule discovery and development initiatives.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}